Cited by CrossRef (8)
- Ankur Varma, Laura Biritxinaga, Rima M. Saliba, Maximilian Stich, Sarah Francesca Jauch, Aimaz Afrough, Medhavi Honhar, Uday R. Popat, Mehnaz A. Shafi, Nina Shah, Qaiser Bashir, Yvonne Dinh, Chitra Hosing, Richard E. Champlin, Muzaffar H. Qazilbash. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation 2017;23:581
- Xuzhao Zhang, Yun Liang, Xian Li, Weiqin Wang, Jiefeng Tong, Yang Xu. Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug. 2020;99:e22642
- Yutaka Tsukune, Makoto Sasaki, Takeshi Odajima, Atsushi Isoda, Morio Matsumoto, Michiaki Koike, Hideto Tamura, Keiichi Moriya, Shigeki Ito, Maki Asahi, Yoichi Imai, Junji Tanaka, Hiroshi Handa, Hiromi Koiso, Sakae Tanosaki, Jian Hua, Masao Hagihara, Yuriko Yahata, Satoko Suzuki, Sumio Watanabe, Hiroki Sugimori, Norio Komatsu. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era. Ann Hematol 2016;95:1465
- Yutaka Tsukune, Makoto Sasaki, Norio Komatsu. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers 2019;11:1819
- Fernando Bessone, Melisa Dirchwolf. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. WJH 2016;8:385
- Apostolos Koffas, Grace E Dolman, Patrick TF Kennedy. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clinical Medicine 2018;18:212
- Benjamin W Teh, Monica A Slavin, Simon J Harrison, Leon J Worth. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Review of Anti-infective Therapy 2015;13:1325
- Hyunsung Park, Do Young Kim, Soo-Jeong Kim, Haerim Chung, Hyunsoo Cho, Ji Eun Jang, June-Won Cheong, Yoo Hong Min, Jae-Woo Song, Jin Seok Kim. HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma. Cancer Res Treat 2018;50:1121